DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism

Information source: University Hospital Inselspital, Berne
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypopituitarism; Hydrocortisone; Lipids; Fatty Acids, Nonesterified; Insulin Sensitivity

Intervention: Hydrocortisone (Drug); Placebo (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University Hospital Inselspital, Berne

Official(s) and/or principal investigator(s):
Emanuel Christ, MD, PhD, Principal Investigator, Affiliation: Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern
Chris Boesch, MD, PhD, Principal Investigator, Affiliation: AMSM; Division of Radiology, University Hopsital of Bern, Inselspital

Overall contact:
Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch

Summary

This study aims at assessing the effect of today's standard of hydrocortisone dosage versus previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL and IHCL) after a standardised fat load followed by a short-term aerobic exercise in patients with corticotropic pituitary insufficiency.

Clinical Details

Official title: The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids (Intrahepatocellular IHCL and Intramyocellular IMCL) in Patients With Corticotropic Hypopituitarism, a Randomised Placebo-controlled Double-blind Trial

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

Change from baseline in flexibility of Intramyocellular Lipids (IMCL) Measured in mmol/L

Change from baseline in flexibility of Intrahepatocellular Lipids (IHCL) Measured in mmol/L

Secondary outcome:

Free Fatty Acids (FFA) availability during exercise before and after additional hydrocortisone/placebo Measured in mmol/L

Flexibility of ectopic fat stores, defined as difference between intramyocellular/intrahepatocellular lipid concentration before and after exercise, and their possible relation to insulin sensitivity before and after additional hydrocortisone/placebo

Free Fatty Acids (FFA) availability during exercise and the possible relation to insulin sensitivity before and after additional hydrocortisone/placebo Measured in mmol/L

Effect of exercise on insulin at baseline

Effect of exercise on insulin at 3 months

Effect of exercise on catecholamines at baseline

Effect of exercise on catecholamines at 3 months

Effect of exercise on growth hormone at baseline

Effect of exercise on growth hormone at 3 months

Effect of exercise on cortisol at baseline

Effect of exercise on cortisol at 3 months

Effect of exercise on lactate at baseline

Effect of exercise on lactate at 3 months

Effect of exercise on glucose at baseline

Effect of exercise on glucose at 3 months

Effect of exercise on inflammatory markers at baseline

Effect of exercise on inflammatory markers at 3 months

Detailed description: Background The investigators and others have shown that long-term hydrocortisone replacement therapy at higher doses of hydrocortisone replacement therapy at higher doses of hydrocortisone replacement (as previously recommended) is associated with higher mortality. The pathophysiology for the association of hydrocortisone-replacement dose and mortality remains unclear. A possible underlying mechanism is nonalcoholic fatty liver disease which is more prevalent in patients with hypopituitarism. Patients with non-alcoholic fatty liver disease are at a higher risk for overall-mortality. It remains to be established whether the insulin resistance, associated with increased intrahepatocellular lipids and increased intramusculoskeletal lipids, is implicated in the pathophysiology of these epidemiological findings. Interestingly, it has been shown that a reduction of hydrocortisone replacement dose from 20-30mg/d to 10-15mg/d resulted in a loss of body fat and a significant decrease of plasma total cholesterol and triglyceride concentration. The effect of IMCL and IHCL is so far unknown. Patients with hypopituitarism with hydrocortisone replacement therapy provide a unique disease model to study the short-term effects of previously recommended dose (higher dose) of hydrocortisone versus lower dose of HC replacement therapy on ectopic lipids (IMCL; IHCL) lipids, as well as on subcutaneous and visceral fat mass and on parameters of insulin resistance. Combining MRI and MR-spectroscopy techniques, different fat mass (subcutaneous and visceral) and ectopic lipids can be repeatedly and non-invasively assessed. Objective To investigate the impact of today's standard of hydrocortisone dosage (lower) versus previous (higher) hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots after a standardised fat load followed by a short-term aerobic exercise in patients with corticotropic pituitary insufficiency. Methods Ectopic lipids are measured by MR-spectroscopy, separate assessment of visceral and subcutaneous fat mass will be performed by MR-imaging, standardized exercise capacity test using spiroergometry. Short-time exercise consists of 2h aerobic cycling at 50% VO2max. Laboratory analysis include lipid profile, free fatty acids, HOMA-Index, hormones.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Written informed consent

- Male and female patients

- Corticotropic pituitary insufficiency

- Capable to exercise during 120 minutes on a bicycle

- Normal ECG during ergometry

Exclusion Criteria

- Concomitant medication with NSAID, anticoagulants, digoxin, salbutamol,

anticonvulsants, cholinesterase inhibitor, pancuronium

- Abnormal liver, renal or thyroid function, heart failure

- Hemophilia

- Diabetes mellitus

- Severe dyslipidemia

- Active neoplasia

- Women who are pregnant or breast feeding

- Intention to become pregnant during the course of the study

- Lack of safe contraception

- Known or suspected non-compliance

- Drug or alcohol abuse

- Inability to follow the procedures of the study

- Participation in another study with investigational drug within the 30 days preceding

and during the study

- Previous enrolment into current study

- Enrolment of the investigator, his/her family members, employees and other dependent

persons

- Inability to exercise

- Contraindications to exposure to a 3 T magnetic field

- Major depression, psychosis, claustrophobia

Locations and Contacts

Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch

Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Berne, Berne 3010, Switzerland; Recruiting
Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch
Emanuel Christ, MD, PhD, Principal Investigator
Additional Information

Related publications:

Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 1997 Apr;37(4):484-93.

Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary. 2008;11(3):279-85. doi: 10.1007/s11102-008-0126-2.

Starting date: January 2015
Last updated: August 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017